Table 4.
Imaging modality by clinical drug development phase
| Imaging modality | Clinical drug development phase | |||||||
|---|---|---|---|---|---|---|---|---|
| Phase 0 | Phase I | Phase II | Phase III | Others | Unknown | Total | p value | |
| PET | 3 (1.7) | 80 (46.0) | 35 (20.1) | 2 (1.1) | 10 (5.7) | 44 (25.3) | 174 (100.0) | |
| SPECT | 0 (0.0) | 6 (16.2) | 9 (24.3) | 2 (5.4) | 2 (5.4) | 18 (48.6) | 37 (100.0) | |
| Total | 3 (1.4) | 86 (40.8) | 44 (20.9) | 4 (1.9) | 12 (5.7) | 62 (29.4) | 211 (100.0) | 0.0184 |
Frequency (row percentage) is shown. The total number of imaging modalities was 211 because three papers reported more than one imaging modality
PET, positron emission tomography; SPECT, single-photon emission computed tomography